Compare Middle Eastern CDMOs across Saudi Arabia, UAE, Jordan, and Israel. Filter by manufacturing type, regulatory approvals, and capacity for regional and global supply.
The Middle East is an emerging pharmaceutical manufacturing region, driven by government diversification strategies (Saudi Vision 2030, UAE industrial policy) and a growing domestic market exceeding $30 billion annually. Jordan has the most established pharmaceutical export industry in the region, with over 80 manufacturing facilities serving MENA markets.
Saudi Arabia is making substantial investments in domestic pharmaceutical manufacturing capacity. The National Industrial Development and Logistics Program (NIDLP) targets 40% local pharmaceutical manufacturing by 2030. This creates opportunities for CDMOs to establish facilities with government support, serving both Saudi domestic demand (largest GCC market) and export to neighboring countries.
Israel stands apart with its advanced biotechnology sector. Israeli CDMOs offer cutting-edge capabilities in biologics, specialty generics, and drug delivery technologies. The country's strong academic-industry connections and innovation ecosystem support advanced manufacturing for global markets. Teva Pharmaceutical's extensive manufacturing network, though primarily captive, has spun off CDMO partnerships.
No companies found in this category yet. Check back soon.
Browse all CDMOsOur AI Matchmaker analyzes your project requirements and matches you with qualified manufacturing partners. Free for buyers.